Provided are a tumor immune enhancer, a pharmaceutical composition thereof, and a preparation method therefor. The enhancer comprises one or more polypeptides using sequences shown in SEQ ID NOs.: 1-9 as core structures, and can be used for preparing tumor vaccines.

Provided are octavalent influenza vaccine compositions comprising eight mRNA, each mRNA comprising an open reading frame encoding a different influenza antigen. Also provided are lipid nanoparticles (LNPs) for delivering said mRNA.

The present disclosure is directed to compositions and methods useful for treating, as well as vaccinating against, SARS-CoV-2 viral infections, including SARS-CoV-2 variant viral infections.

The present invention relates generally to the field of immunogenic compositions containing volatile salts. In certain embodiments, compositions and methods disclosed herein relate to producing and using novel combinations to create frozen immunogenic agents bound to adjuvant having improved formulations and improved consistency of distribution of adjuvant for storage and subsequent delivery to a subject in need thereof.

Methods for inducing an immune response against tau protein in a subject suffering from a neurodegenerative disease, disorder or condition, such as Alzheimer's Disease, are described. The methods include administering a liposomal priming composition containing tau peptides, preferably phosphorylated tau peptides, and a conjugate boosting composition containing tau peptides, preferably phosphorylated tau peptides, conjugated to an immunogenic carrier.

The invention relates to a unit dose of a dengue vaccine composition and methods and uses for preventing dengue disease and methods for stimulating an immune response to all four dengue virus serotypes in a subject or subject population. The unit dose of a dengue vaccine composition includes constructs of each dengue serotype, such as TDV-1, TDV-2, TDV-3 and TDV-4, at various concentrations in order to improve protection from dengue infection.

The present disclosure provides methods for inducing an immune response to hepatitis C virus (HCV) in an individual. The present disclosure provides methods for treating an HCV infection in an individual.

The present disclosure provides vaccine compositions for use against enterotoxigenic Escherichia coli (ETEC) comprising EtpA and EatA. EtpA and EatA are prevalent amount diverse ETEC isolates and display significant sequence conservation. In an aspect, the disclosure encompasses a vaccine composition comprising EtpA and EatA. In another aspect, the disclosure encompasses a method of protecting against intestinal colonization of enterotoxigenic Escherichia coli (ETEC) in a subject. The method comprises administering to the subject an effective amount of a vaccine composition comprising EatA and EtpA.

Provided herein is a vaccine comprising a Porcine Epidemic Diarrhea Virus (PEDV) antigen. The antigen can be a consensus antigen. Also disclosed herein is a method of treating a porcine in need thereof, by administering the vaccine to the porcine.

A menu of mutations was developed that is useful in fine-tuning the attenuation and growth characteristics of dengue virus vaccines.